Literature DB >> 16755591

Transcatheter closure of patent foramen ovale in older adults.

Fuad M Kiblawi1, Robert J Sommer, Sean G Levchuck.   

Abstract

OBJECTIVES: Comparing results of patent foramen ovale (PFO) closure in older and younger patient cohorts.
BACKGROUND: The literature pertaining to stroke and PFO has focused on patients <55 years of age.
METHODS: Between March 2000 and December 2003, 456 consecutive stroke/transient ischemic attack (TIA) patients (14.2-91.1 years, mean 51.4 +/- 15.5) underwent successful closure of PFO with a CardioSEAL Septal Occluder by one operator at five hospitals. Of the 456 patients, 184 (40.4%) were >55 years of age at the time of the procedure (mean 66.9 +/- 8.3 years) and comprise the subject group (OLDER). The remaining 272 patients (mean 41.1 +/- 7.7) comprise the control group (YOUNGER). Data were collected prospectively in a registry type format.
RESULTS: Minor procedural complications were comparable: 7/184 (3.8%) OLDER vs. 12/272 (4.4%) YOUNGER (P = NS). In the follow-up period (1-45 months, mean = 17.8 +/- 11.1), there was no significant difference in the rate of recurrent stroke/TIA, headaches, or late unrelated death. Forty OLDER patients and 47 YOUNGER developed new onset atrial arrhythmia (P = NS). The incidence of new onset atrial fibrillation (AF), however, was significantly higher in OLDER (14/40 OLDER and only 2/47 YOUNGER, P < 0.025). All patients who were in normal sinus rhythm (NSR) before the procedure are in NSR at last follow-up.
CONCLUSIONS: Older patients should not be excluded from PFO closure. The procedure seems as safe and effective in preventing recurrent stroke in the older, as in the younger population. Older patients seem more prone to developing AF. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16755591     DOI: 10.1002/ccd.20722

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

Review 1.  Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence.

Authors:  Georgios D Kitsios; Issa J Dahabreh; Abd Moain Abu Dabrh; David E Thaler; David M Kent
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

Review 2.  PFO Closure for Cryptogenic Stroke.

Authors:  Sabreena J Gillow; Vivien H Lee
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

3.  Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.

Authors:  Scott E Kasner; Balakumar Swaminathan; Pablo Lavados; Mukul Sharma; Keith Muir; Roland Veltkamp; Sebastian F Ameriso; Matthias Endres; Helmi Lutsep; Steven R Messé; J David Spence; Krassen Nedeltechev; Kanjana Perera; Gustavo Santo; Veronica Olavarria; Arne Lindgren; Shrikant Bangdiwala; Ashkan Shoamanesh; Scott D Berkowitz; Hardi Mundl; Stuart J Connolly; Robert G Hart
Journal:  Lancet Neurol       Date:  2018-09-28       Impact factor: 44.182

4.  Percutaneous transcatheter closure of high-risk patent foramen ovale in the elderly.

Authors:  Hiroya Takafuji; Shinobu Hosokawa; Riyo Ogura; Yoshikazu Hiasa
Journal:  Heart Vessels       Date:  2019-03-13       Impact factor: 2.037

5.  Long-term efficacy after closure of patent foramen ovale for ischemic neurological events in young adults: A systematic review and meta-analysis.

Authors:  Liang Xu; Xuemei Pan; Chang Zhou; Jie Li; Fangyuan Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.